{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T19:20:28Z","timestamp":1648581628963},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.eimc.2011.04.004","type":"journal-article","created":{"date-parts":[[2011,6,25]],"date-time":"2011-06-25T08:06:59Z","timestamp":1308989219000},"page":"609-614","source":"Crossref","is-referenced-by-count":0,"title":["De la gen\u00e9tica a la gen\u00f3mica en el dise\u00f1o de nuevas vacunas contra la tuberculosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Virgilio","family":"Bocanegra-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Valencia-Delgadillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Cruz-Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Cant\u00fa-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gildardo","family":"Rivera-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Prisco","family":"Palma-Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2011.04.004_bib0005","unstructured":"WHO. Vaccine-preventable diseases: monitoring system-2009 Global Summary; 2009."},{"key":"10.1016\/j.eimc.2011.04.004_bib0010","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.shpsc.2005.09.003","article-title":"The \u201cexperimental stable\u201d of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933","volume":"36","author":"Bonah","year":"2005","journal-title":"Stud Hist Philos Biol Biomed Sci"},{"key":"10.1016\/j.eimc.2011.04.004_bib0015","first-page":"119","article-title":"Influence of sex, age & nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India","volume":"123","author":"Narayanan","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.eimc.2011.04.004_bib0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","article-title":"Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis","volume":"70","author":"Brandt","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0025","first-page":"103","article-title":"Comments on the new analysis of the Chingleput BCG trial","volume":"123","author":"Rook","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.eimc.2011.04.004_bib0030","first-page":"205","article-title":"The geographic location (latitude) of studies evaluating protective effect of BCG vaccine and it's efficacy\/effectiveness against tuberculosis","volume":"51","author":"Zodpey","year":"2007","journal-title":"Indian J Public Health"},{"key":"10.1016\/j.eimc.2011.04.004_bib0035","first-page":"531","article-title":"The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available antibodies","volume":"134","author":"Abou-Zeid","year":"1988","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0040","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1128\/IAI.72.10.6148-6150.2004","article-title":"Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model","volume":"72","author":"Olsen","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0045","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.vaccine.2006.03.072","article-title":"Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31","volume":"24","author":"Agger","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0050","doi-asserted-by":"crossref","first-page":"e5930","DOI":"10.1371\/journal.pone.0005930","article-title":"Protection and polyfunctional T cells induced by Ag85B-TB10.4\/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose","volume":"4","author":"Aagaard","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.eimc.2011.04.004_bib0055","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.4049\/jimmunol.177.9.6353","article-title":"Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity","volume":"177","author":"Dietrich","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0060","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1128\/IAI.73.9.5817-5826.2005","article-title":"Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system","volume":"73","author":"Rosenkrands","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.0818-9641.2002.01143.x","article-title":"Improving vaccines against tuberculosis","volume":"81","author":"Britton","year":"2003","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/1750743X.1.1.31","article-title":"Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection","volume":"1","author":"Giri","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.eimc.2011.04.004_bib0075","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1128\/IAI.72.12.6945-6950.2004","article-title":"A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice","volume":"72","author":"Ferraz","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0080","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1128\/IAI.67.9.4780-4786.1999","article-title":"Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences","volume":"67","author":"Li","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0085","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0090","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in na\u00efve human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0095","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 86A boost BCG-primed and naturally adquiered antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.eimc.2011.04.004_bib0100","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1128\/CVI.00047-10","article-title":"Investigating the induction of vaccine-induced Th17 and regulatory T cells in healthy, Mycobacterium bovis BCG-immunized adults vaccinated with a new tuberculosis vaccine, MVA85A","volume":"17","author":"De Cassan","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0105","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immnogenicity and protective efficacy against M. tuberculosis of bacilli Calmette Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","article-title":"Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells","volume":"40","author":"Scriba","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0115","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/IAI.00004-07","article-title":"Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon","volume":"75","author":"Radosevic","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0120","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/mt.2009.60","article-title":"Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis","volume":"17","author":"Mu","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.eimc.2011.04.004_bib0125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","article-title":"Recombinant BCG exporting ESAT-6 confers enhanced protection againt tuberculosis","volume":"9","author":"Pym","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.eimc.2011.04.004_bib0130","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.4049\/jimmunol.174.6.3570","article-title":"Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system","volume":"174","author":"Majlessi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0135","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1128\/IAI.00434-08","article-title":"A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG","volume":"76","author":"Tullius","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.vaccine.2008.10.034","article-title":"Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells","volume":"27","author":"Badell","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0145","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1073\/pnas.93.2.934","article-title":"Manipulation and potentiation of antimycobacterial immunity using recombinant bacilli Calmette-Guerin strains that secrete cytokines","volume":"93","author":"Murray","year":"1996","journal-title":"Prot Natl Acad Sci USA"},{"key":"10.1016\/j.eimc.2011.04.004_bib0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","article-title":"Recombinant bacille Calmetter-Guerin (BCG) expressing human interferon alpha 2B demonstrates enhanced immunogenicity","volume":"123","author":"Luo","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1440-1711.2002.01078.x","article-title":"Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin","volume":"80","author":"Young","year":"2002","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0160","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e9rin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eimc.2011.04.004_bib0165","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/422394","article-title":"Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Mycobacterium bovis bacille Calmette-Gu\u00e9rin induce equal protection","volume":"190","author":"Mollenkopf","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.04.004_bib0170","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1128\/IAI.69.2.1442-1150.2001","article-title":"Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccines candidates","volume":"69","author":"Smith","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0175","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2006.03.017","article-title":"The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs","volume":"24","author":"Mart\u00edn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14712598.8.2.201","article-title":"Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials","volume":"8","author":"Asensio","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.eimc.2011.04.004_bib0185","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/IAI.72.5.3031-3037.2004","article-title":"Protection elicited by a double leucine and pantothenate auxotroph of M. tuberculosis in guinea pigs","volume":"72","author":"Sampson","year":"2004","journal-title":"Infec Immnu"},{"key":"10.1016\/j.eimc.2011.04.004_bib0190","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1128\/IAI.73.2.1196-1203.2005","article-title":"Long term protection against tuberculosis following vaccination with severe attenuated double lysine and pantothenate auxotroph of M. tuberculosis","volume":"73","author":"Sambandamurthy","year":"2005","journal-title":"Infec Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0195","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2009.05.050","article-title":"Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates","volume":"27","author":"Larsen","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0200","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.eimc.2011.04.004_bib0205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","article-title":"Genes required for mycobacterial growth defined by high density mutagenesis","volume":"48","author":"Sassetti","year":"2003","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0210","doi-asserted-by":"crossref","unstructured":"Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci USA. 2003b;100:12989\u201394.","DOI":"10.1073\/pnas.2134250100"},{"key":"10.1016\/j.eimc.2011.04.004_bib0215","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/IAI.66.4.1277-1281.1998","article-title":"Macrophage receptors for Mycobacterium tuberculosis","volume":"66","author":"Ernst","year":"1998","journal-title":"Infect Immun"},{"key":"10.1016\/j.eimc.2011.04.004_bib0220","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/infdis\/170.5.1229","article-title":"Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1","volume":"170","author":"Hirsch","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eimc.2011.04.004_bib0225","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1084\/jem.20051239","article-title":"The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis","volume":"202","author":"Kang","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.eimc.2011.04.004_bib0230","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.micpath.2005.06.002","article-title":"The 19-kDa antigen of Mycobacterium tuberculosis is a major adhesin that binds the mannose receptor of THP-1 monocytic cells and promotes phagocytosis of mycobacteria","volume":"39","author":"D\u00edaz-Silvestre","year":"2005","journal-title":"Microb Pathog"},{"key":"10.1016\/j.eimc.2011.04.004_bib0235","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1021\/pr800756a","article-title":"Mycobacterium tuberculosis glycoproteomics based on ConA-lectin affinity capture of mannosylated proteins","volume":"8","author":"Gonz\u00e1lez-Zamorano","year":"2009","journal-title":"J Proteome Res"},{"key":"10.1016\/j.eimc.2011.04.004_bib0240","first-page":"37","article-title":"IgG antibody level to mycobacterial glycoprotein in pulmonary tuberculosis by ELISA","volume":"71","author":"Kato","year":"1987","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eimc.2011.04.004_bib0245","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1128\/CMR.11.3.514","article-title":"Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis","volume":"11","author":"Glatman-Freedman","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.eimc.2011.04.004_bib0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1579-2129(07)60055-X","article-title":"Innovative strategies to diagnose and monitor tuberculosis patients","volume":"43","author":"Palma-Nicol\u00e1s","year":"2007","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0255","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-3083.1994.tb03417.x","article-title":"Individuals from different populations identify multiple and diverse T-cell determinants on mycobacterial HSP70","volume":"39","author":"Adams","year":"1994","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tube.2004.09.005","article-title":"Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes","volume":"85","author":"McMurry","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.eimc.2011.04.004_bib0265","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ymeth.2004.06.002","article-title":"Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE","volume":"34","author":"Bian","year":"2004","journal-title":"Methods"},{"key":"10.1016\/j.eimc.2011.04.004_bib0270","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.vaccine.2005.01.059","article-title":"Developing an epitope-driven tuberculosis (TB) vaccine","volume":"23","author":"De Groot","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0275","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/156652407780831584","article-title":"Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics. ELISpot assays, and HLA transgenic mice","volume":"7","author":"McMurry","year":"2007","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.eimc.2011.04.004_bib0280","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.vaccine.2009.12.083","article-title":"The second Geneva Consensus: Recommendations for novel live TB vaccines","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0285","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-0711-3-10","article-title":"A second-generation anti TB vaccine is long overdue","volume":"3","author":"Casta\u00f1\u00f3n-Arreola","year":"2004","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.eimc.2011.04.004_bib0290","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1016\/j.vaccine.2005.07.045","article-title":"A review of vaccine research and development: tuberculosis","volume":"23","author":"Girard","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.eimc.2011.04.004_bib0295","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1073\/pnas.0511240103","article-title":"Variable host-pathogen compatibility in Mycobacterium tuberculosis","volume":"103","author":"Gagneux","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.eimc.2011.04.004_bib0300","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/CVI.00006-10","article-title":"Highly persistent and effective prime\/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant","volume":"17","author":"Kolibab","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.eimc.2011.04.004_bib0305","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/hv.8570","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02A: Tolerability and immunogenicity in humans","volume":"5","author":"Von Eschen","year":"2009","journal-title":"Hum Vaccin"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X11001601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X11001601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T18:06:08Z","timestamp":1592676368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X11001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0213005X11001601"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2011.04.004","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}